Netupitant/palonosetron

Netupitant/palonosetron
Combination of
Netupitant	NK1 receptor antagonist
Palonosetron	5-HT₃ receptor antagonist
Clinical data
Trade names	Akynzeo

Netupitant/palonosetron (Akynzeo) is a fixed dose combination drug for prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy.^[1] Netupitant is an NK1 receptor antagonist and palonosetron is a 5-HT₃ receptor antagonist.

References

↑ "FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy". Food and Drug Administration. October 10, 2014.

Antiemetics (A04)

5-HT3 Serotonin ion channel antagonists	Alosetron Azasetron Bemesetron Cilansetron Clozapine Dazopride Dolasetron Granisetron Lerisetron Metoclopramide Mianserin Mirtazapine Olanzapine Ondansetron Palonosetron Quetiapine Ramosetron Ricasetron Tropisetron Zatosetron

5-HT Serotonin G-protein receptor antagonists	Clozapine Cyproheptadine Hydroxyzine Olanzapine Risperidone Ziprasidone

CB₁ Agonists (Cannabinoids)	Dronabinol Nabilone Tetrahydrocannabinol (cannabis)

D₂/D₃ Antagonists	Alizapride Bromopride Chlorpromazine Clebopride Domperidone Haloperidol Hydroxyzine Itopride Metoclopramide Metopimazine Prochlorperazine Thiethylperazine

H₁ antagonists (Antihistamines)	Cyclizine Dimenhydrinate Diphenhydramine Hydroxyzine Meclozine Promethazine

mACh antagonists (Anticholinergics)	Atropine Diphenhydramine Hydroxyzine (very mild) Hyoscyamine Scopolamine

NK₁ Antagonists	Aprepitant Casopitant Ezlopitant Fosaprepitant Maropitant Netupitant Rolapitant Vestipitant

Others	Cerium oxalate Dexamethasone Lorazepam Midazolam Propofol Trimethobenzamide

This article is issued from Wikipedia - version of the Friday, April 24, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.